Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study

• Paul K. Keith,
• Juthaporn Cowan,
• Amin Kanani,
• Harold Kim,
• Gina Lacuesta,
• Jason K. Lee,
• Jie Chen,
• Michelle Park,
• André Gladiator

Affiliations

Paul K. Keith

Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University

Juthaporn Cowan

Division of Infectious Diseases, Department of Medicine, Department of Biochemistry, Microbiology, and Immunology; Centre for Infection, Immunity and Inflammation, University of Ottawa, The Ottawa Hospital Research Institute

Amin Kanani

Division of Allergy and Clinical Immunology, Department of Medicine, St. Paul’s Hospital, University of British Columbia

Harold Kim

Division of Clinical Immunology and Allergy, Department of Medicine, McMaster University

Gina Lacuesta

Department of Medicine, Dalhousie University

Jason K. Lee

Chair of Toronto Allergists and Evidence Based Medical Educator

Jie Chen

Takeda Development Center Americas, Inc.

Michelle Park

Takeda Development Center Americas, Inc.

André Gladiator

Glattpark‑Opfikon, Takeda Pharmaceuticals International AG